Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
A phase 3 trial of Zanzalintinib, Atezolizumab, Regorafenib in colorectal cancer, run by Exelixis, active and no longer recruiting.
Overview
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05425940 by Exelixis, with 901 participants enrolled, started 2022-09-07 and due to reach its primary completion in 2026-06-16. Interventions recorded: XL092, Atezolizumab, Regorafenib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shares Zanzalintinib, Exelixis.
- TrialZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Shares Zanzalintinib, Exelixis.
- TrialStudy of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece
Shares Exelixis, Atezolizumab.
- TrialTATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Shares Regorafenib, Colorectal cancer.
- TrialStudy of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Shares Exelixis, Atezolizumab.
- TrialA Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Shares Atezolizumab, Colorectal cancer.
- TrialA Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Shares Atezolizumab, Colorectal cancer.
- TrialAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Shares Regorafenib, Colorectal cancer.